Latest / Breaking News To Trading Moves
The Merck-Revolution Split: Valuation Discipline and Biotech Fallout
Merck Walks Away From Revolution Medicines Talks, Triggering Biotech Deal-Premium Reset
Merck $MRK is no longer in talks to buy Revolution Medicines $RVMD, according to a Wall Street Journal report. The talks reportedly cooled over price, and notes say talks could restart or another bidder could show up.
Why this matters to markets
This is a classic M and A premium unwind. When a rumored buyout fades, the target often drops as the takeover premium comes out. For Merck, walking away can be read as valuation discipline, but it also keeps the pressure on to build the post-Keytruda growth…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.